2cureX, Germany receives an additional grant for adapting IndiTreat® to guide immunotherapy of ovarian cancer patients
Copenhagen – April 6, 2020 – 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that 2cureX’s German subsidiary 2cureX GmbH (“2cureX”) has received another grant from the German Federal Ministry of Education and Research to adapt the company´s IndiTreat® test for individualizing immunotherapy for patients suffering from ovarian cancer. This project is conducted in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, “UKE”).In January 2017 2cureX and UKE were granted net 810.216 EUR to adapt the IndiTreat[®] test to ovarian cancer